Company news

Telomir Pharmaceuticals, Inc. news in 2024

Telomir Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

December 22, 2024

Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation

December 16, 2024

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

December 11, 2024

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

December 2, 2024

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

November 20, 2024

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo, to Lead IND and INAD Applications for Human and Veterinary Indications

September 5, 2024

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

September 3, 2024

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

August 11, 2024

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

July 1, 2024

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

May 29, 2024

Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support

May 15, 2024

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

April 15, 2024

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

March 25, 2024

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

March 21, 2024

Telomir Pharmaceuticals Announces Closing of Initial Public Offering

February 12, 2024

Decks in 2024